Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TriSalus Life Sciences (TLSIW) EBT (2022 - 2025)

Historic EBT for TriSalus Life Sciences (TLSIW) over the last 4 years, with Q3 2025 value amounting to -$10.8 million.

  • TriSalus Life Sciences' EBT fell 34987.51% to -$10.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$39.6 million, marking a year-over-year increase of 2877.92%. This contributed to the annual value of -$30.0 million for FY2024, which is 4939.01% up from last year.
  • According to the latest figures from Q3 2025, TriSalus Life Sciences' EBT is -$10.8 million, which was down 34987.51% from -$8.3 million recorded in Q2 2025.
  • TriSalus Life Sciences' 5-year EBT high stood at $2.8 million for Q1 2022, and its period low was -$35.6 million during Q4 2023.
  • For the 4-year period, TriSalus Life Sciences' EBT averaged around -$9.6 million, with its median value being -$8.3 million (2025).
  • The largest annual percentage gain for TriSalus Life Sciences' EBT in the last 5 years was 8239.22% (2023), contrasted with its biggest fall of 67822.91% (2023).
  • Quarter analysis of 4 years shows TriSalus Life Sciences' EBT stood at -$22.5 million in 2022, then tumbled by 58.14% to -$35.6 million in 2023, then skyrocketed by 71.63% to -$10.1 million in 2024, then decreased by 6.89% to -$10.8 million in 2025.
  • Its EBT was -$10.8 million in Q3 2025, compared to -$8.3 million in Q2 2025 and -$10.4 million in Q1 2025.